TTM
$1.48B
YoY change
+43.7%
5Y CAGR
+29.2%
Peak year (2025)
$1.36B
Cumulative EBITDA
$4.47B
EBITDA history chart for DexCom (DXCM) from 2000 to 2025
Latest: $1.36B
EBITDA growth chart for DexCom (DXCM) from 2000 to 2025
Latest: +43.7%
EBITDA history table for DexCom (DXCM) from 2000 to 2025
| 2025 | $1.36B | +43.7% | +$412.80M | ||
| 2024 | $945.70M | +3.2% | +$29.00M | ||
| 2023 | $916.70M | +62.2% | +$351.40M | ||
| 2022 | $565.30M | +49.7% | +$187.80M | ||
| 2021 | $377.50M | +0.2% | +$700.00K | ||
| 2020 | $376.80M | +76.7% | +$163.60M | ||
| 2019 | $213.20M | -385.4% | +$287.90M | ||
| 2018 | −$74.70M | +279.2% | −$55.00M | ||
| 2017 | −$19.70M | -60.0% | +$29.50M | ||
| 2016 | −$49.20M | +6.3% | −$2.90M | ||
| 2015 | −$46.30M | +253.4% | −$33.20M | ||
| 2014 | −$13.10M | -40.2% | +$8.80M | ||
| 2013 | −$21.90M | -55.3% | +$27.10M | ||
| 2012 | −$49.00M | +19.6% | −$8.02M | ||
| 2011 | −$40.98M | -19.9% | +$10.21M | ||
| 2010 | −$51.19M | +18.7% | −$8.08M | ||
| 2009 | −$43.11M | -13.4% | +$6.68M | ||
| 2008 | −$49.79M | +14.9% | −$6.45M | ||
| 2007 | −$43.34M | -7.0% | +$3.28M | ||
| 2006 | −$46.62M | +57.0% | −$16.92M | ||
| 2005 | −$29.70M | +126.2% | −$16.57M | ||
| 2004 | −$13.13M | +33.6% | −$3.30M | ||
| 2003 | −$9.83M | +55.8% | −$3.52M | ||
| 2002 | −$6.31M | -6.1% | +$413.09K | ||
| 2001 | −$6.72M | +67.5% | −$2.71M | ||
| 2000 | −$4.01M | — | — |
- 2025$1.36B+43.7%
- 2024$945.70M+3.2%
- 2023$916.70M+62.2%
- 2022$565.30M+49.7%
- 2021$377.50M+0.2%
- 2020$376.80M+76.7%
- 2019$213.20M-385.4%
- 2018−$74.70M+279.2%
- 2017−$19.70M-60.0%
- 2016−$49.20M+6.3%
- 2015−$46.30M+253.4%
- 2014−$13.10M-40.2%
- 2013−$21.90M-55.3%
- 2012−$49.00M+19.6%
- 2011−$40.98M-19.9%
- 2010−$51.19M+18.7%
- 2009−$43.11M-13.4%
- 2008−$49.79M+14.9%
- 2007−$43.34M-7.0%
- 2006−$46.62M+57.0%
- 2005−$29.70M+126.2%
- 2004−$13.13M+33.6%
- 2003−$9.83M+55.8%
- 2002−$6.31M-6.1%
- 2001−$6.72M+67.5%
- 2000−$4.01M—
EBITDA values are taken from DexCom's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's current EBITDA (TTM) is $1.48B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of DexCom (DXCM) EBITDA is $1.36B – surged 43.7% year-over-year.
DexCom EBITDA has grown for 7 consecutive years, with a +29.2% compound annual growth rate over 2020–2025 (5 years).
The record annual EBITDA stands at $1.36B, reached in 2025; the historical low of −$74.70M was recorded in 2018.
DexCom EBITDA by Year
DexCom EBITDA 2025: $1.36B
DexCom EBITDA in 2025 was $1.36B, surged 43.7% from 2024. This figure represents the highest annual value in the available history.
DexCom EBITDA 2024: $945.70M
2024's EBITDA for DexCom came in at $945.70M, edged up 3.2% from 2023.
DexCom EBITDA 2023: $916.70M
DexCom posted EBITDA of $916.70M in 2023, surged 62.2% from 2022.
DexCom EBITDA 2022: $565.30M
In 2022, DexCom reported EBITDA of $565.30M, surged 49.7% from 2021.
DexCom EBITDA 2021: $377.50M
DexCom EBITDA in 2021 was $377.50M.
See more financial history for DexCom (DXCM).
Sector peers by EBITDA
Healthcare peers of DexCom (DXCM), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation